Xi to Meet EU Chiefs at Downsized Summit Hit by Trade, Ukraine
Tensions spanning trade to the war in Ukraine are casting a pall over an event that coincides with the 50th anniversary of the establishment of China-EU diplomatic ties. The meeting has been cut short from two days to one at Beijing's request, Bloomberg News has reported, with the venue changed from Brussels to the Chinese capital after Xi refused to travel to Europe for the talks.
The Chinese leader as well as Premier Li Qiang will meet throughout the day with European Commission President Ursula von der Leyen and the head of the European Council, Antonio Costa, according to an EU official. The meeting follows the EU's summit with Japan held in Tokyo Wednesday.
While there are no plans to issue a joint communique, the EU intends to release a statement listing the main messages it delivered, according to people familiar with the matter, who spoke on condition of anonymity.
The tensions on display this week contrast with hope at the height of the trade war unleashed by Donald Trump for China to repair ties with the EU. Back then, Beijing appeared to be positioning itself as a more reliable partner as Trump alienated the bloc. Now, deep disagreements are once again marring the relationship.
Tensions flared in April with Beijing's decision to impose export controls on rare earth magnets, which shook European car companies and other sectors.
Brussels also takes issue with what it considers as Beijing's support for Moscow. The EU on Friday sanctioned two Chinese banks and five China-based companies as part of its latest measures against Russia.
Trade ties are another source of frustration. The Asian nation's goods trade surplus reached almost $143 billion in the first half of this year, a record for any six-month period, according to data released last week.
The EU inflamed trade tensions when it imposed tariffs on Chinese electric vehicles last year in a bid to ward off a flood of cheap imports. In response, China launched anti-dumping probes into European brandy, dairy and pork.
With assistance from Iain Rogers and Jorge Valero.
This article was generated from an automated news agency feed without modifications to text.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India.com
18 minutes ago
- India.com
Israel-Gaza War Puts Billion-Dollar IMEC Project At Risk; India-Saudi Strains Leave China Smiling – Why This Corridor Matters
New Delhi: The war in Gaza is not only claiming lives. It is dismantling billion-dollar plans stretching from India to Europe. Among them is the India-Middle East-Europe Economic Corridor (IMEC), a flagship connectivity project backed by India, the United States, Saudi Arabia, the European Union and the United Arab Emirates (UAE). The project had a grand vision. Announced during the G20 Summit in New Delhi in September 2023, the IMEC aimed to link India with Europe via the Middle East. A series of modern rail networks, ports, pipelines and digital infrastructure would form its spine. Israel was expected to play a central role as the corridor's critical junction. But war changed that. The fighting in Gaza has triggered diplomatic cold fronts across the Arab world. Hostage crises and hunger deaths have gripped global headlines. Behind the scenes, the IMEC blueprint is beginning to look fragile. Several conversations linked to the corridor's normalisation process have stopped. The air of political instability has raised new doubts. Investors are now cautious. Talks have lost momentum. Security concerns loom larger. Reports from Israeli media outlets such Ynet cite growing fears that the project may now face indefinite delays. The timing has worked in Beijing's favour. The IMEC was widely seen as a counter to China's Belt and Road Initiative (BRI), with its own web of global infrastructure alliances. A stalled IMEC is a strategic breather for China. It removes immediate competition from a rival corridor that was built to tilt trade flows away from Chinese influence. For India, in addition to being a transport network, the IMEC was a geopolitical leap. With 47 trillion dollars in combined GDP between its partners, it held the potential to upgrade India's role in global trade. The corridor also fit into New Delhi's broader push to develop digital public infrastructure, enhance green energy ties and open secure channels to Europe and the Americas. Though the dream has not died, it has dimmed. The longer the war in Gaza drags on, the harder it gets for IMEC stakeholders to keep the political will alive. Saudi Arabia's frustration over Israel's war posture is deepening. Strategic cohesion among partner countries is thinning. The risk of indefinite pause is no longer a whisper. Whether the IMEC becomes reality or remains a footnote in G20 speeches now depends on what unfolds on the ground in Gaza.
Time of India
41 minutes ago
- Time of India
Hims & Hers Q2 revenue drop shakes stock—Hims crashes 11% after first-ever revenue decline, is the weight-loss drug hype finally fading?
Why did Hims & Hers stock fall after earnings? Live Events Current Price : $63.35 : $63.35 Day Range : $54.82 – $65.54 : $54.82 – $65.54 Open : $64.00 : $64.00 Market Cap: $6.56 Billion P/E Ratio : 39.93 : 39.93 Volume: 35.5M Earnings beat estimates, but Wall Street stays cautious Is the GLP‑1 weight-loss business at risk? Regulatory uncertainty : With the FDA rolling back flexibility on compounded versions of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. : With the FDA rolling back flexibility on of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. Legal challenges : The company recently ended its supply relationship with Novo Nordisk , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. : The company recently ended its supply relationship with , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. Competitive pressure: Big players like Eli Lilly and Novo Nordisk are dominating the branded drug market, making it harder for telehealth companies offering generics to compete on pricing and trust. Hims keeps full-year guidance intact—thanks to international expansion Subscriber growth remains strong despite volatility What investors should watch going forward Future of compounded GLP-1s: Regulatory and legal outcomes could limit Hims' ability to sell compounded semaglutide at scale. Profitability trends: Will margins hold up as more competition floods the market and Hims scales its personalized offerings? Subscriber growth and retention: Continued engagement in non-weight loss categories will be key to long-term stability. Zava integration: The success or failure of this acquisition could make or break Hims' international ambitions. Hims still growing, but cracks are showing FAQs: (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Hims & Hers Health (NYSE: HIMS), the fast-growing telehealth company known for its personalized care plans and buzzy entry into the weight-loss market, saw its stock drop by over 11% after reporting second-quarter 2025 earnings. While revenue jumped 73% year-over-year, the company missed Wall Street expectations and posted its first-ever, raising questions about the future of itsDespite its rapid annual growth, Hims & Hers posted, missing the analyst estimate of. The real concern? Revenue dropped from, marking the first quarter-over-quarter decline since the company went stock currently trades at, regaining some ground after hitting an intraday low of. Despite opening at, it remains volatile, with an intraday high ofThe market reacted sharply to the company's revenue miss—$544.8 million vs. $552 million expected—even though earnings per share beat expectations and subscriber numbers remained strong. Most of the company's revenue stemmed from its GLP-1-based obesity and diabetes treatments, a booming but increasingly scrutinized business regulatory pressures, lawsuits from Novo Nordisk, and tighter FDA rules on compounded semaglutide, Hims faces headwinds in its fastest-growing segment. However, with a market cap of over $6.5 billion, a P/E ratio of 39.93, and forward-looking confidence via its Zava acquisition, the company is still betting big on growth in both the U.S. and were caught off guard, as the slowdown came amid soaring demand forlike semaglutide, a compound similar to the active ingredient in Wegovy and the profit front, Hims reported an adjusted EPS of $0.19, beating the Street's expectation of $0.15. However, the revenue miss overshadowed this earnings appeared more concerned about the underlying business momentum, particularly in the obesity treatment space, which has been a major driver of Hims' recent biggest growth story in recent quarters has been its expansion into GLP-1 weight-loss treatments, which brought in around $190 million in Q2 alone. However, a few red flags have emerged:Despite the Q2 shortfall, Hims & Hers stuck to its full-year outlook. The company reaffirmed its 2025 guidance of $2.3 billion to $2.4 billion in revenue and $295 million to $335 million in adjusted EBITDA.A big reason? The Zava acquisition, a European telehealth platform, which is expected to contribute around $50 million in new revenue this year. This suggests Hims is betting heavily on international growth to offset some of its domestic bright spot in the report was Hims' growing subscriber base. The company now serves over 2.4 million active subscribers, with nearly 70% enrolled in personalized treatment plans that span weight loss, hair care, sexual health, and mental Andrew Dudum emphasized that the company is leaning deeper into its long-term strategy of personalized digital healthcare, aiming to build loyalty and customer lifetime value across multiple product you're following Hims & Hers stock or investing in telehealth companies focused on the obesity drug boom, here are four key things to monitor:Hims & Hers Health has come a long way as a digital-first wellness brand with a bold strategy around weight-loss drugs and personalized healthcare. But the 11% stock drop shows investor sentiment is shifting, especially as its flagship obesity business faces regulatory hurdles and supply now, the company's strong year-over-year growth and firm 2025 guidance offer some reassurance. But with rising competition, tighter FDA rules, and legal pressure, Hims will need to prove that its success isn't just tied to a single product wave—but a durable, trusted digital care company missed revenue estimates and saw its first-ever sequential drop in due to FDA scrutiny and legal issues around compounded semaglutide.
United News of India
an hour ago
- United News of India
GHMC partners with Google, wil launch GenAI- based Pilot Project
Hyderabad, Aug 4 (UNnI) In a groundbreaking move to redefine urban governance, the Greater Hyderabad Municipal Corporation (GHMC) has partnered with Google to launch a GenAI-based pilot project aimed at solving key civic challenges and improving citizen services across the city. This initiative is part of Telangana Chief Minister A. Revanth Reddy's vision to transform Hyderabad into a Gen AI-enabled city. A virtual Google Meet was convened today evening to discuss the roadmap for this ambitious project. The session was attended by *MA&UD Secretary Ilambarthi, GHMC Commissioner RV Karnan, IT Additional Commissioner Anuraag Jayanthi and senior representatives from Google. The GenAI (advanced to AI) pilot will explore futuristic, tech-driven solutions to common urban issues and focus on creating a responsive and intelligent city administration. Speaking on the occasion, Karnan said 'This collaboration marks a milestone in GHMC's digital transformation journey'. Once tested successfully, these AI tools will be scaled city-wide, enabling Hyderabad to serve as a national model for smart, tech-powered urban living, said the GHMC Commissioner. This partnership with Google is not just a tech experiment but a step toward building a smarter, healthier, and more efficient Hyderabad for all citizens, Karnan added. Key areas under Google's AI focus include: AI-Enabled Government and Citizen Services; GenAI-Powered Search Bar for Government Websites; Conversational Chatbots and AI Search Tools for Government Employees; AI-Based Citizen Enquiry Classification System; Blockchain-Enabled Verifiable Credentials for G2C Services; AI-Based Tender Evaluation System; Smart Parking Management Using AI; AI for Solid Waste Management Optimization; Automated Form Filling for Public Applications;Real-Time Tracking of Public Buses via Google Maps; AI-Driven Road Safety and Traffic Models;Google Cloud APIs for FHIR-Compliant Health Records ;Citywide Health Analytics Platform ;AI for Vector-Borne Disease Detection & Prevention ;AI Monitoring of Lake Dumping and C&D Waste and Manya'- An AI Assistant for ASHA Workers. UNI KNR RKM
